The spiny dendrites of striatal projection neurons integrate synaptic inputs of different origins to regulate movement. It has long been known that these dendrites lose spines and display atrophic features in Parkinson's disease (PD), but the significance of these morphological changes has remained unknown. Some recent studies reveal a remarkable structural plasticity of striatal spines in parkinsonian rodents treated with L-3,4-dihydroxyphenylalanine (L-DOPA), and they demonstrate an association between this plasticity and the development of dyskinesia. These studies used different approaches and animal models, which possibly explains why they emphasize different plastic changes as being most closely linked to dyskinesia (such as a growth ...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Changing the strength of synaptic connections between neurons is widely assumed to be the mechanism ...
Loss of dopamine in Parkinson's disease is hypothesized to impede movement by inducing hypo- and hyp...
Dopamine depletion in Parkinson's disease (PD) produces dendritic spine loss in striatal medium spin...
Background: L-3,4-dihydroxyphenylalanine (L-DOPA)–induced dyskinesia is an incapacitating complicati...
The development of L-DOPA-induced dyskinesia (LID) is attributed to plastic responses triggered by d...
Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by the loss of dopamine (DA)...
Dopamine (DA) replacement therapy with l-DOPA remains the most effective treatment for Parkinson's d...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
Parkinson's disease (PD) is a neurodegenerative disorder where the midbrain dopaminergic neurons are...
Striatal function adapts to the loss of nigrostriatal dopaminergic input in Parkinson's disease (PD)...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
Repetitive stimulation of the corticostriatal pathway can cause either a long-lasting increase, or a...
Striatal dopamine (DA) denervation results in a significant loss of dendritic spines on medium spiny...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Changing the strength of synaptic connections between neurons is widely assumed to be the mechanism ...
Loss of dopamine in Parkinson's disease is hypothesized to impede movement by inducing hypo- and hyp...
Dopamine depletion in Parkinson's disease (PD) produces dendritic spine loss in striatal medium spin...
Background: L-3,4-dihydroxyphenylalanine (L-DOPA)–induced dyskinesia is an incapacitating complicati...
The development of L-DOPA-induced dyskinesia (LID) is attributed to plastic responses triggered by d...
Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by the loss of dopamine (DA)...
Dopamine (DA) replacement therapy with l-DOPA remains the most effective treatment for Parkinson's d...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
Parkinson's disease (PD) is a neurodegenerative disorder where the midbrain dopaminergic neurons are...
Striatal function adapts to the loss of nigrostriatal dopaminergic input in Parkinson's disease (PD)...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
Repetitive stimulation of the corticostriatal pathway can cause either a long-lasting increase, or a...
Striatal dopamine (DA) denervation results in a significant loss of dendritic spines on medium spiny...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Changing the strength of synaptic connections between neurons is widely assumed to be the mechanism ...
Loss of dopamine in Parkinson's disease is hypothesized to impede movement by inducing hypo- and hyp...